依达拉奉联合尼莫地平序贯疗法治疗脑出血的临床疗效及其对患者细胞免疫功能、神经功能的影响

Clinical Effect of Edaravone Combined with Sequential Therapy of Nimodipine on Cerebral Hemorrhage and Its Impact on Cellular Immune Function and Neurological Function

目的观察依达拉奉联合尼莫地平序贯疗法治疗脑出血的临床疗效,并探讨其对患者细胞免疫功能、神经功能的影响。方法选取2015年2月—2017年2月无锡市人民医院收治的脑出血患者100例,采用随机数字表法分为对照组和观察组,每组50例。对照组患者给予尼莫地平序贯治疗,观察组患者在对照组基础上加用依达拉奉治疗;两组患者均连续治疗1个月。比较两组患者临床疗效,治疗前及治疗后7 d、1个月CD_3^+细胞分数、CD_4^+/CD_8^+细胞比值、美国国立卫生研究院卒中量表(NIHSS)评分,并观察两组患者治疗期间不良反应发生情况。结果观察组患者临床疗效优于对照组(P<0.05)。时间与方法在CD_3^+细胞分数、CD_4^+/CD_8^+细胞比值上存在交互作用(P<0.05);时间在CD_3^+细胞分数、CD_4^+/CD_8^+细胞比值上主效应显著(P<0.05);方法在CD_3^+细胞分数、CD_4^+/CD_8^+细胞比值上主效应显著(P<0.05);治疗后7 d、1个月观察组患者CD_3^+细胞分数、CD_4^+/CD_8^+细胞比值高于对照组(P<0.05)。时间与方法在NIHSS评分上存在交互作用(P<0.05);时间在NIHSS评分上主效应显著(P<0.05);方法在NIHSS评分上主效应显著(P<0.05);治疗后7 d、1个月观察组患者NIHSS评分低于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论依达拉奉联合尼莫地平序贯疗法治疗脑出血的临床疗效确切,并可有效改善患者细胞免疫功能、神经功能,且安全性高。

Objective To observe the clinical effect of edaravone combined with sequential therapy of nimodipine on cerebral hemorrhage,to investigate its impact on cellular immune function and neurological function.Methods A total of 100 patients with cerebral hemorrhage were selected in the People's Hospital of Wuxi from February 2015 to February 2017,and they were divided into control group and observation group according to random number table,each of 50 cases.Patients in control group received sequential therapy of nimodipine,while patients in observation group received edaravone combined with nimodipine;both groups continuously treated for 1 month.Clinical effect,CD3+cell percentage,CD4+/CD8+cell ratio and NIHSS score before treatment,7 days and 1 month after treatment were compared between the two groups,and incidence of adverse reactions was observed during treatment.Results Clinical effect in observation group was statistically significantly better than that in control group(P<0.05).There was statistically significant interaction between time and method in CD3+cell percentage and CD4+/CD8+cell ratio(P<0.05);main effect of time was statistically significant in CD3+cell percentage and CD4+/CD8+cell ratio(P<0.05);main effect of method was statistically significant in CD3+cell percentage and CD4+/CD8+cell ratio(P<0.05);CD3+cell percentage and CD4+/CD8+cell ratio in observation group were statistically significantly higher than those in control group 7 days and 1 month after treatment(P<0.05).There was statistically significant interaction between time and method in NIHSS score(P<0.05);main effect of time was statistically significant in NIHSS score(P<0.05);main effect of method was statistically significant in NIHSS score(P<0.05);NIHSS score in observation group were statistically significantly lower than those in control group 7 days and 1 month after treatment,respectively(P<0.05).No statistically significant differences of incidence of adverse reactions between the two groups.Conclusion Edaravone combined with sequential therapy of nimodipine has certain clinical effect in treating cerebral hemorrhage,can effectively improve the neurological function and cellular immune function,with high safey.